[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nordic Biotic Sp. z o.o.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100629130","effects-of-probiotic-supplementation-on-stress-and-anxiety-in-students-100629130",false,"NCT07470645","Effects of Probiotic Supplementation on Stress and Anxiety in Students","The Efficacy of Probiotic Supplementation in Reducing Stress and Anxiety: A Randomized, Placebo-Controlled Study in Healthy Students During the Examination Period","PROfoS","Inclusion Criteria:\n\n* Male or female students aged 18-40 years\n* At least moderate stress (DASS-21 Stress score ≥10)\n* Mild anxiety (DASS-21 Anxiety score 6-13)\n* No clinical depression (DASS-21 Depression score ≤9)\n* Willingness to maintain usual diet, physical activity, and intake of caffeinated beverages during the study\n* Written informed consent\n\nExclusion Criteria:\n\n* Irritable bowel syndrome (Rome IV criteria) or any chronic intestinal disease (including celiac disease)\n* Known food allergies, immunodeficiency disorders, or immunosuppressive treatment\n* Antibiotic use within 4 weeks prior to screening\n* Any psychiatric illness within the past 5 years\n* Any malignant disease or autoimmune or allergic diseases (e.g., atopic dermatitis, asthma)\n* Use of systemic psychotropic medications or steroids; use of topical corticosteroid creams within 4 weeks prior to screening\n* Pregnancy, breastfeeding, or plans to become pregnant during the study\n* Probiotic or prebiotic consumption or planned dietary changes within 4 weeks prior to screening\n* Heavy caffeine consumption (\\>4 cups of 300 mL coffee per day)\n* Drug or alcohol addiction or regular use of recreational drugs\n* Smoking more than 10 cigarettes per day","ALL","18 Years","40 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized, double-blind, placebo-controlled study evaluates the efficacy and safety of an 8-week probiotic supplementation (Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 in total daily dose 1 × 10¹⁰ CFU or matching placebo) in reducing perceived stress and anxiety, and improvement related psychological parameters in healthy university students during the examination period. The primary outcome is the change in Perceived Stress Scale (PSS-10) score at week 5 and week 8 of interevention compared to placebo. The secondary outcomes are the changes in DASS-21 subscales (Stress, Anxiety, Depression), State-Trait Anxiety Inventory - State version scale (STAI-S), Sense of Coherence Scale (SOC-29), Pittsburgh Sleep Quality Index (PSQI), self-reported gastrointestinal symptoms (Likert scale) and incidence of adverse events during the 8-week lasting interventional study.",[28,29,30,31],"Stress","Anxiety","Sleep","Gastro-intestinal Symptoms in Healthy Subjects",[33,28,29,34],"Probiotics","Gut-brain axis","NOT_YET_RECRUITING","2026-03-13",{"date":38,"type":39},"2026-03-17","ACTUAL",{"date":41,"type":22},"2026-04-20",{"date":43,"type":22},"2026-08-15",{"name":45,"class":46},"Nordic Biotic Sp. z o.o.","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100614162","probiotics-in-functional-dyspepsia-100614162","NCT07276009","Probiotics in Functional Dyspepsia","The Effect of Multi-strain Probiotic Formulation on Gastrointestinal Symptoms, Quality of Life and Mental Health in Patients With Functional Dyspepsia: a Randomized Dietary Trial","ProPepsis","Inclusion Criteria:\n\n1. Age 18-65 years\n2. Diagnosis of Functional Dyspepsia based on Rome IV criteria, with symptoms present for at least 3 months, and symptom onset at least 6 months before diagnosis, including:\n\n   * Postprandial fullness\n   * Early satiation\n   * Epigastric pain or burning\n   * (with no evidence of structural disease explaining symptoms)\n3. Moderate to severe symptom severity at baseline, as defined by a validated scale (e.g., NDI or global symptom score)\n4. Normal upper GI endoscopy within the last 12 months (or at screening), excluding structural disease (e.g., peptic ulcer, malignancy)\n5. Negative for H. pylori (either previously treated successfully or tested negative within study screening)\n6. Ability and willingness to provide informed consent and comply with study procedures\n7. Stable medication use, if any, for at least 4 weeks before screening (e.g., PPIs, antidepressants, laxatives)\n\nExclusion Criteria:\n\n1. Evidence of structural GI disease (e.g., peptic ulcer, gastric cancer, celiac disease) on recent or screening endoscopy\n2. History of gastrointestinal surgery affecting stomach or small intestine (except appendectomy or cholecystectomy)\n3. Positive test for H. pylori during screening (or untreated known infection)\n4. Current or recent use (within 4 weeks) of antibiotics, pre-, pro- or postbiotics, unless part of study protocol\n5. Use of medications affecting GI motility (e.g., prokinetics, opioids, anticholinergics) within 2-4 weeks before enrollment\n6. Overlap with other functional GI disorders (except IBS) if they are the dominant complaint, unless your protocol allows overlap\n7. Clinically significant psychiatric illness (e.g., major depression, schizophrenia) that may interfere with symptom reporting or adherence\n8. Severe systemic or metabolic disease (e.g., uncontrolled diabetes, renal or hepatic failure)\n9. Pregnancy or lactation, or intention to become pregnant during the study period\n10. Participation in another clinical trial within the past 3 months\n11. Known allergy or intolerance to study product components","65 Years",{"count":58,"type":22},60,[25],"The goal of this clinical trial is to learn whether a multi-strain probiotic can reduce digestive symptoms and improve quality of life in adults with functional dyspepsia. The main questions it aims to answer are:\n\n* Does the probiotic reduce symptoms such as fullness after meals, bloating, stomach discomfort, and early satiation?\n* Does the probiotic improve emotional well-being, including stress, anxiety, and mood? Researchers will compare the probiotic to a placebo (a look-alike capsule with no active ingredients) to see if the probiotic truly helps adults with functional dyspepsia.\n\nParticipants will:\n\n* Take one capsule of the probiotic or placebo once daily before meals for 60 days\n* Complete questionnaires about their digestive symptoms at the start, 1 month, and 2 months\n* Complete surveys on stress, anxiety, depression, and quality of life at the start and 2 months\n* Attend scheduled study visits for checkups and assessments",[62],"Functional Dyspepsia","2026-01-07",{"date":65,"type":39},"2026-01-08",{"date":67,"type":22},"2026-01-05",{"date":69,"type":22},"2026-05-01",{"name":45,"class":46},""]